- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2013
- Public Summary Document (PSD) July 2013 PBAC Meeting - PDF
Ruxolitinib – July 2013
Ruxolitinib, tablets, 5 mg, 15 mg and 20 mg, Jakavi®
Last updated
8 November 2023